Growth In The Liposomal Drug Delivery Devices Market Is Being Driven By Global Increase In Cancer Cases Fuels Growth Of Liposomal Drug Delivery Devices Market
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
From Its 2026 Market Size, What Value Is The Liposomal Drug Delivery Devices Market Projected To Reach By 2030?
The liposomal drug delivery devices market has experienced significant growth recently. This market is projected to expand from $5.34 billion in 2025 to $6.01 billion in 2026, reflecting a compound annual growth rate (CAGR) of 12.4%. The expansion observed in the historic period can be attributed to advancements in nanotechnology-based drug delivery, the increasing prevalence of cancer, the broader availability of injectable drug formulations, the rising adoption of liposomal antifungal therapies, and growing investments in pharmaceutical research.
The market for liposomal drug delivery devices is projected to experience substantial expansion over the coming years. Its valuation is anticipated to reach $9.49 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 12.1%. This projected growth is driven by several factors, including a heightened demand for targeted cancer therapies, the broader application of personalized medicine strategies, the increasing uptake of sophisticated drug delivery platforms, growing financial commitments to biologics and vaccines, and a sharpened emphasis on minimizing drug toxicity. Key trends anticipated during this period encompass the wider acceptance of targeted drug delivery systems, an increase in the utilization of pegylated liposomal formulations, their expanded use in oncology treatments, the development of liposomal vaccines and antifungals, and a greater emphasis on achieving controlled drug release.
Access Your Free Sample Report For In-Depth Market Analysis:
Which Strong Drivers Are Impacting The Liposomal Drug Delivery Devices Market Growth?
The global rise in cancer occurrences is projected to stimulate the growth of the liposomal drug delivery devices market moving forward. Cancer encompasses a broad category of illnesses defined by the uncontrolled proliferation and spread of abnormal cells, with its escalating incidence reflecting the combined influence of an aging population, environmental risk factors, and evolving lifestyle choices. As the prevalence of cancer expands, there is an increased demand for advanced, targeted therapies such as liposomal formulations, which can enhance drug delivery, mitigate systemic toxicity, and boost treatment efficacy. For instance, in February 2024, the World Health Organization reported an estimated 20 million new cancer cases in 2022, with projections indicating a rise to 35 million by 2050, signifying a 77% increase. Thus, the growing worldwide burden of cancer is fueling the expansion of the liposomal drug delivery devices market.
How Is The Liposomal Drug Delivery Devices Market Organized By Segment Classification?
The liposomal drug delivery devices market covered in this report is segmented –
1) By Type: Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B, Other Types
2) By Application: Fungal Diseases, Cancer Therapy, Pain Management, Viral Vaccines, Photodynamic Therapy
3) By End User: Hospitals, Diagnostic Centers, Ambulatory Surgery Centers/Clinics, Other End Users
Subsegments:
1) By Liposomal Doxorubicin: Conventional Liposomal Doxorubicin, PEGylated Liposomal Doxorubicin
2) By Liposomal Paclitaxel: Conventional Liposomal Paclitaxel, PEGylated Liposomal Paclitaxel
3) By Liposomal Amphotericin B: Conventional Liposomal Amphotericin B, PEGylated Liposomal Amphotericin B
4) By Other Types: Liposomal Irinotecan, Liposomal Vincristine, Liposomal Cytarabine
Which Trends Are Contributing To Changes In The Liposomal Drug Delivery Devices Market?
Major companies in the liposomal drug delivery market are introducing innovative products, such as hydrochloride liposome injection, to gain a competitive advantage. Researchers have been developing liposomal nanostructures aimed at improving patient compliance through less frequent doses while maintaining efficacy. For instance, in August 2024, Lupin Ltd., an India-based pharma company, launched Doxorubicin Hydrochloride Liposome Injection 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL). The Doxorubicin Hydrochloride Liposome Injection had an estimated annual sales figure of approximately USD 40.9 million in the U.S. market as of June 2024. This strategically positions Lupin within the oncology segment as it expands its portfolio to include this important cancer treatment option. Lupin’s dedication to improving patient health outcomes is evident through this launch, as it aims to provide effective treatment alternatives in a competitive pharmaceutical landscape.
Who Are The Industry Participants Involved In The Liposomal Drug Delivery Devices Market?
Major companies operating in the liposomal drug delivery devices market are Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., Novartis AG, Gilead Sciences Inc., Ipsen SA, Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co. Ltd., Nanomerics Ltd., Luye Pharma Group Ltd., Leadiant Biosciences Inc., Pacira Biosciences Inc., Nippon Kayaku Co. Ltd., Celsion Corporation, Acrotech Biopharma Inc., Aphios Pharma LLC, CytImmune Sciences Inc., NanoSphere Health Sciences Inc., Cel-Sci Corporation, Lipoid GmbH, Liposome Company Inc., Liposome Research Days Corporation, Taiwan Liposome Company
Get The Full Liposomal Drug Delivery Devices Market Report:
Which Region Has The Greatest Market Share In The Liposomal Drug Delivery Devices Market?
North America was the largest region in the liposomal drug delivery devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liposomal drug delivery devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Liposomal Drug Delivery Devices Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Liposomal Drug Delivery Devices Market 2026, By The Business Research Company
Liposuction Surgery Devices Market Report 2026
https://www.thebusinessresearchcompany.com/report/liposuction-surgery-devices-global-market-report
Pharmaceutical Drug Delivery Market Report 2026
https://www.thebusinessresearchcompany.com/report/pharmaceutical-drug-delivery-global-market-report
Liposomal Doxorubicin Market Report 2026
https://www.thebusinessresearchcompany.com/report/liposomal-doxorubicin-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
